Celecoxib/diacerein - Cadila Healthcare

Drug Profile

Celecoxib/diacerein - Cadila Healthcare

Alternative Names: Diacerein/celecoxib - Cadila Healthcare

Latest Information Update: 22 Jul 2015

Price : $50

At a glance

  • Originator Cadila Healthcare
  • Class Anthraquinones; Antirheumatics; Nonsteroidal anti-inflammatories; Pyrazoles; Small molecules; Sulfonamides
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors; Interleukin 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Osteoarthritis

Most Recent Events

  • 22 Jul 2015 No recent reports on development identified - Phase-III for Osteoarthritis in India (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top